Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Adaptimmune Therapeutics ( (ADAP) ) has shared an update.
Adaptimmune Therapeutics announced structural changes, including the resignation of two UK-based executives, as part of its ongoing restructuring efforts. The company plans to focus more operations in the U.S. and aims for significant cost savings, impacting its market positioning and stakeholder relations.
More about Adaptimmune Therapeutics
Adaptimmune Therapeutics is a fully integrated cell therapy company focused on redefining cancer treatment using its engineered T cell receptor (TCR) platform. The company develops personalized medicines aimed at targeting and destroying solid tumor cancers to improve the cancer treatment experience for patients.
YTD Price Performance: -23.29%
Average Trading Volume: 1,800,338
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $155.1M
Find detailed analytics on ADAP stock on TipRanks’ Stock Analysis page.
